News - Appointments

Claude Knopf, a former Novartis executive, has joined ImCheck Therapeutics SAS of Marseille, France as chief business officer. He will be located in Boston, US. ImCheck is developing antibody drug candidates targeting the butyrophilin superfamily of immune system regulators.

Edwin Moses, the former chief executive of Ablynx, has been appointed chair of the board of directors of Sensorion SA, a developer of treatments for hearing loss disorders. Dr Moses led Ablynx for more than 14 years until its acquisition by Sanofi SA in 2018.

Josefin-Beate Holz, an experienced drug developer, has joined Storm Therapeutics Ltd as chief medical officer to help advance the company’s small molecule therapies modulating RNA epigenetics.

Compass Pathways Ltd has recruited Trevor Mill from Biogen Inc to lead the research and development of its psilocybin therapy for treatment-resistant depression and other projects. At Biogen he was head of global safety and regulatory sciences.

Matthew Gall, an industry veteran, has joined iTeos Therapeutics Inc as chief financial officer to help advance the company’s early-stage immuno-oncology portfolio.

Ann Rhoads, an experienced financial executive, has been appointed to the board of directors of iTeos Therapeutics SA, a Belgium-based immuno-oncology company.

The Swiss chemicals and biotechnology company Lonza Group AG has appointed Pierre-Alain Ruffieux, currently head of global pharma technical operations at Roche, as its new chief executive. Dr Ruffie

Cedrik Britten, the former head of oncology cell therapy research at GlaxoSmithKline Plc, has joined Immatics Biotechnologies GmbH as chief medical officer. The biopharmaceutical company discovers a

The gene and cell therapy group Oxford Biomedica plc has appointed Roch Doliveux as non-executive chairman. Dr Doliveux was previously chief executive of UCB SA.

The biopharmaceutical company Aruvant Sciences, Inc has appointed V.